Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee options carry a $0.5817 exercise price and vest over four years, subject to continuous service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Invivyd (IVVD) granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 common shares on November 1, 2026.
The employment inducement grants were made under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The $0.5817 per-share exercise price equals the stock’s October 30, 2026 closing price. Each option vests over four years: 25% on the first anniversary of the employee’s start date, followed by equal monthly installments, subject to continuous service. The options have a 10-year term.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.175,000 common shares underlying employee options at a $0.5817 exercise price represent potential dilution.
Key Figures
- Options granted
- 175,000 shares
- Aggregate grant to seven newly hired non-executive employees
- Exercise price
- $0.5817 per share
- Closing price on October 30, 2026
- Vesting schedule
- Four years; 25% at first anniversary
- Remaining shares vest in equal monthly installments, subject to continuous service
- Option term
- 10 years
- Options granted under the 2026 Inducement Plan
Historical Context
-
Prior grant covered 157,500 shares for six hires at $0.8165 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
The options have a per share exercise price of
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.